Longeveron Inc. (LGVN)
| Previous Close | 2.6800 |
| Open | 2.7000 |
| Bid | 2.6600 x 1000 |
| Ask | 2.7300 x 1800 |
| Day's Range | 2.6900 - 2.7600 |
| 52 Week Range | 2.5000 - 16.7700 |
| Volume | |
| Avg. Volume | 43,830 |
| Market Cap | 57.116M |
| Beta (5Y Monthly) | 0.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9000 |
| Earnings Date | May 14, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.40 |
- Simply Wall St.
Longeveron (NASDAQ:LGVN shareholders incur further losses as stock declines 18% this week, taking one-year losses to 51%
Investing in stocks comes with the risk that the share price will fall. Anyone who held Longeveron Inc. ( NASDAQ:LGVN...
- GlobeNewswire
Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-- Full results from ELPIS I trial published in European Heart Journal Open – -- First patient to be randomized in Japan Aging-Related Phase 2 study in Q1 – -- Conference call scheduled for 8:30 a.m. ET today -- MIAMI, March 10, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the fourth quart
- GlobeNewswire
Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023
Live conference call on Friday, March 10 at 8:30 a.m. ETMIAMI, March 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its fourth quarter and full year 2022 financial results on Friday, March 10, 2023 before the open of the U.S. financial markets. Management will host a conference call to discusss the Company’s fina
